Author Archives: Lu Rahman

#Drug development #Immunology / Virology & Vaccines

Why Nexelis is ‘changing the R&D paradigm in vaccines’

Benoit Bouche, President and CEO, Nexelis, told Lu Rahman about the company's recent acquisition and what it means for the business and the vaccine sector. Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. The company –… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Novavax and Canadian government purchase agreement for COVID-19 vaccine

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option… Read More

#Covid-19 #News #Trending News

#AI / data analytics / healthtech / informatics #Drug discovery

NovAliX partners with Chemical.AI to develop artificial intelligence toolkit for drug discovery

NovAliX, a drug discovery-focused contract research organisation (CRO), and Chemical.AI, an artificial intelligence (AI) company leveraging human expertise and cutting-edge AI technology for chemistry and pharmaceuticals, have created a strategic It is hoped that the affiliation will help create the most relevant AI solutions for drug developers. NovAliX brings 20… Read More

#Editor's Choice #News #Trending News

#Mass spectrometry / NMR

Unraveling the phosphoproteome with Trapped Ion Mobility Spectrometry (TIMS)

By Professor Yasushi Ishihama, Laboratory of Molecular and Cellular BioAnalysis, Kyoto University Mass spectrometry (MS) is now widely used in protein biochemistry and proteomics to identify and characterise proteins, with technology constantly evolving to achieve higher depths of coverage, speed, and sensitivity. For example, tandem mass spectrometry (MS/MS) is a… Read More

#Exclusive Content #News

#Biologics #Cell therapy

Solentim new standards in productivity with antibodies workflow solutions

Solentim, expert in cell therapy workflows enabling the creation, isolation and characterisation of high value cells, has launched two solutions to enhance the development of therapeutic antibodies. Icon is a benchtop system for the rapid stratification of high productivity clones and Studius is a proprietary software platform that delivers data… Read More

#News

#Automation / robotics

SPT Labtech acquisition of Apricot Designs

SPT Labtech, a global player in the design and development of automated instrumentation and consumables for life science applications, has announced the acquisition of Apricot Designs, California. Apricot Designs has established a 30-year track record supporting increasingly complex and evolving laboratory research requirements with the design and manufacture of multichannel… Read More

#News

#Assay development & optimisation #Immunology / Virology & Vaccines

Nexelis aquires GSK Vaccines’ German clinical bioanalytical lab

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany. The Clinical Laboratory… Read More

#News

#Automation / robotics #SLAS 2021

Uncover the benefits of automating workflows: PerkinElmer at SLAS2021

Automating workflows allows labs to do more with less says PerkinElmer who will be at SLAS2021 on booth 33. Laboratories face many challenges today which are leading them to automate and miniaturise their workflows to alleviate these challenges. PerkinElmer has range of solutions including automating entire workflows based on needs… Read More

#News

#Biologics / Biotechnology #Clinical trials #Oncology

The importance of partnership and innovation in oncology

Fostering synergies to accelerate innovation in oncology and make it attractive for partners has been the MATWIN motto for over a decade, writes CEO Lucia Robert, MATWIN who outlines the organisations’s work MATWIN is a French open-innovation platform dedicated to supporting innovation in oncology. For more than ten years, its… Read More

#Cancer Research #Exclusive Content #News

#Imaging #SLAS 2021

Visit Yokogawa Life Innovations team at SLAS2021 Digital

Yokogawa Life Innovations says its goal is to solve the needs of researchers, laboratories, and other organisations that seek to improve and automate their processes via a high-content platform. The company will be on booth 142 to discuss how it can help with high-content imaging platforms, microlens dual-spinning disc technology,… Read More

#News

#Cell and gene therapy #Covid-19

Akron Biotech agreement with Octapharma to produce virally inactivated human AB serum

Akron Biotechnology has signed an exclusive global agreement to manufacture virally inactivated human AB serum for the cell therapy market using Octaplas, Octapharma’s pooled, solvent-detergent treated human plasma. Akron Biotech is a manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialisation. Switzerland-based Octapharma is one of… Read More

#News

#Gene editing #Stem cells

Single-cell cloning technology from iotaSciences at SLAS2021

iotaSciences, a company that develops technologies for single-cell cloning is giving exhibitor tutorials at SLAS2021 Digital. These tutorials will explore some of the key challenges of single-cell cloning for gene editing, stem cells and other applications. During the tutorials we will introduce our new cloning platform and provide customer data… Read More

#News

#CRISPR #Drug discovery #SLAS 2021

Horizon Discovery at SLAS2021 Digital

Horizon Discovery is sponsoring SLAS 2021. The company will be holding an innovative tutorial presentation on booth 114 which will cover the use of both pooled and arrayed screens in the drug discovery pipeline. Topics covered include: Arrayed screens in primary immune cells with co-culture endpoints Pooled CRISPR knockout screens with… Read More

#Editor's Choice #News

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#Biotechnology

Innovation and opportunity: Biotech at its best

Lu Rahman looks at the role of the biotech sector in the development of new therapeutics and why this industry is a vital element in drug discovery For reasons we would clearly have preferred not to happen, the global spotlight has  - understandably - been on the biotech sector since… Read More

#Market Reports #News